Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine for Opioid-induced Hyperalgesia in Chronic Pain
NCT02192398Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2014
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of guanfacine in opioid-induced hyperalgesia (OIH) and chronic pain (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Numeric Pain Score at 4 weeks. Started Sep 2014; status: terminated.
02
Drugs
guanfacine
03
Conditions
opioid-induced hyperalgesia (OIH)chronic pain
Beyond the preview
Go deeper on NCT02192398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02192398.